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 Abstract
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. While
there are a number of well-recognized prognostic biomarkers at diagnosis, the most
powerful independent prognostic factor is the response of the leukemia to induction
chemotherapy (Campana and Pui: Blood 129 (2017) 1913–1918). Given the potential
for machine learning to improve precision medicine, we tested its capacity to monitor
disease in children undergoing ALL treatment. Diagnostic and on-treatment bone mar-
row samples were labeled with an ALL-discriminating antibody combination and ana-
lyzed by imaging flow cytometry. Ignoring the fluorescent markers and using only
features extracted from bright-field and dark-field cell images, a deep learning model
was able to identify ALL cells at an accuracy of >88%. This antibody-free, single cell
method is cheap, quick, and could be adapted to a simple, laser-free cytometer to allow
automated, point-of-care testing to detect slow early responders. Adaptation to other
types of leukemia is feasible, which would revolutionize residual disease monitoring.
© 2020 The Authors. Cytometry Part A published by Wiley Periodicals, Inc. on behalf of International Society
for Advancement of Cytometry.
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QUANTIFICATION of persisting leukemia in bone marrow and/or peripheral blood
during initial therapy has become standard of care to enable risk-directed therapy,
where more intensive therapy is given to slow responders, who are at a higher risk
of relapse (1). Such stratification has contributed to current overall survival rates
approaching 90% (2). In addition, it has allowed the de-escalation of chemothera-
peutic dose and thus lessened toxicity in children deemed to be at low risk of
relapse, without impacting on cure (3).
Traditionally, persisting leukemia is assessed by morphology to define complete
remission (<5% ALL cells), and to identify slow early responders, often defined as >25%
ALL cells at Day 8 or 15 following therapy initiation. More sensitive techniques are then
used to identify leukemia that is below the limit of detection based on visual assessment
under a microscope, known as minimal residual disease (MRD). Malignant leukemia cells
can be difficult for experts to accurately identify by morphology and can be mistaken for
benign immature B-cell precursors, particularly in regenerating marrow. Two recent stud-
ies have highlighted the need for more accurate methodologies to improve, and possibly
replace, visual assessment of morphology in evaluating disease response (4,5).
The two principal residual disease assessment methodologies for ALL are
molecular analyses of antigen receptor gene rearrangements or flow cytometry of
aberrant immunophenotypes (6). Fundamental to residual disease detection by flow
cytometry is the characterization of a leukemia-associated immunophenotype at
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diagnosis. This is a four to ten-antibody assay, in which the
leukemic cells fall into so-called empty spaces within scatter
plots, distinct from regions housing normal lymphocyte pro-
genitors (Fig. S1 and S2). It can thus discriminate and quan-
tify leukemic cells in “on-treatment” samples (7). Both
methods of ALL detection are highly specialized, require spe-
cific reagents and extensive training, and are thus slow, labor
intensive, and costly. For resource-poor countries, costs,
travel, and access to specialist laboratories prohibit residual
disease-defined optimized treatment; and in some centers,
even morphological analyses to determine complete remission
or slow early response are done by tele-pathology (8). In
addition, leukemia cells in some children cannot be quantified
by either method due to the absence of “trackable” molecular
or cellular features for their particular leukemia (6).
Recently, flow cytometry has been integrated with fluo-
rescence microscopy to create imaging flow cytometry (IFC),
where an image of each cell is captured as it flows past a
light source and a charge-coupled device (CCD) detector
(9). IFC combines the high throughput capacity of flow
cytometry with the spatial image information of multiple
fluorescence channels as well as the bright-field, similar to
the transmitted light image, and dark-field, equivalent to
side scatter in conventional flow cytometry (10). The high-
content data rapidly captured using IFC is well-suited to
classification of cell phenotypes by machine learning, partic-
ularly deep learning, given the large number of training
images required to apply deep convolutional neural net-
works (Figs. S3, S4). In previous work, we demonstrated the
use of both traditional machine learning (11) and deep con-
volutional neural networks (12) to classify cell cycle phases
in ~34,000 Jurkat cells using only the bright-field and dark-
field channels from IFC, eliminating the need for cell cycle
markers or DNA stains. We wondered whether deep con-
volutional neural networks might be able to detect leukemic
cells from bone marrow samples of ALL patients using few
or no fluorescent markers.
MATERIALS AND METHODS
Patients
Bone marrow samples from children (less than 18 years) who
presented with B lineage ALL within the northern region of
England (October 2013 to July 2015) were used in this study.
They were obtained from the Newcastle Hematology Biobank
following project approval (reference 2002/11 and 07/H906).
The children were registered on the UKALL2011 protocol
and were treated with three to four drugs during the
induction phase of treatment when on-treatment samples
were assessed. Clinical details of the patients used in the study
are shown in Supporting Information Table S1.
Flow Cytometry
Flow MRD was performed according to the UK standardized
method (13). Briefly, samples were collected into Acid Citrate
Dextrose and with red cells lysed using a standard ammo-
nium chloride procedure. Biomarker labeling was done using
fluorescent-conjugated antibodies such as CD45-APCH7,
CD10-PECy7, CD19-APC, CD34-PerCP (all from BD Biosci-
ences, Plymouth, UK) and nuclear staining by Syto41
(Molecular probes, Loughborough, UK). Flow cytometric
measurement was done on a BD FACs Canto II equipped
with 488-nm (blue), 633-nm (red), and 405-nm (violet) lasers,
with a target number of 50,000 cells for diagnostic samples
and >300,000 for “on-treatment” samples. For analysis, an
expert-guided sequential manual gating strategy was applied:
Lymphoid cells were first gated on forward and side scatters,
followed by CD19+, low side scatter cells, then refined inspec-
tion on CD19+CD34— and CD19+/CD34+ double positive
cells. Finally, the expression of CD10 along with CD45 was
assessed in the CD19+CD34+ and CD34—CD19+ populations
to discriminate ALL cells from normal B cells. Samples were
considered positive if the number of leukemic cells identified
was equal to or greater than 0.01% (i.e. the percentage of leu-
kemic cells over the total number of nucleated cells), provid-
ing at least 50 clustered events were apparent.
Imaging Flow Cytometry and Ground Truth
Generation
Bone marrow samples were lysed with Lyse/Fix 5x Buffer
(BD Biosciences) and labeled with CD45-APCH7, CD10-PE,
CD34-PE Texas Red, CD19-APC, DAPI, and p65-FITC. The lat-
ter was included as an antigen not recognized to play a part in
the leukemia-associated immunophenotype (LAIP). IFC mea-
surement was conducted using a dual camera ImageStream X
MarkII system (10) (Amnis, Seattle, WA), equipped with
488 nm, 405 nm, 561 nm, and 642 nm excitation lasers. Data
were collected at 40× magnification, pixel size 0.3 × 0.3 μm.
Bright-field illumination was collected in channels 1 (camera
1, 430 nm–480 nm) and 9 (camera 2, 570 nm–595 nm). Dark-
field illumination was collected in channel 6 (camera 1, 745 nm
– 800 nm) from a 758 nm laser source. Emission from CD10-PE
was measured from the 488 nm laser in channel 3 (560 nm–
595 nm), Texas Red emission was measured from the 488 nm
laser in channel 4 (595 nm–660 nm), CD19-APC from the
642 nm laser in channel 11 (660 nm–745 nm), CD45-APCH7
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from the 654 nm laser in channel 12 (740 nm–800 nm) and
finally DAPI emission was measured from the 405 nm laser in
channel 7 (430 nm–505 nm). Standard flow cytometric compen-
sation procedure was applied in each sample.
Data analysis first started with the exclusion of clumped
cells and out-of-focus cells based on aspect ratios, size, and
gradient root mean square of typical noncellular events
(Figs. S1 and S2). We then constructed pairwise 2-D scatter
plots and performed the manual sequential gating to identify
ALL cells as for the standardized flow method. In addition,
we identified normal B cells (CD19+, CD34−, CD45+, and
CD10+/−) and classified cells with high side scatter, CD19+
Figure 1. Sample partitioning strategy for training, validation, inference, and avoiding overfitting. Samples were split for training
(including validation), testing (Test 1–3) and hold-out (Test 4). Training/validation set contained pooled data of 19 entries from 15 patients.
Samples were collected and measured at the time of presentation (abbreviated as “pres”) and after round(s) of treatments (noted as days
after treatment). Test set 1 contained manually gated ground-truth populations for leukemic blasts, normal lymphocytes and other cell
types (Fig. 2A-C). Test set 2, which contains DAPI-positive, in-focus single white blood cells, was designed to validate whether the learned
algorithms were able to derive a correct residual disease (MRD) readout, that is, percentage of leukemic cells within the total number of
white cells in the bone marrow sample (Fig. 2D). Note: Although some training data and Test set 2 were generated from the same
patients, the training sets use a small number of individually annotated healthy/leukemic cells, while Test set 2 presents a large number
of unannotated cells. Test set 3 (>200,000 single cells in total) was conducted with stained/unstained samples in a condition with or
without laser illumination, confirming that the performance of the trained neural network was not dependent on the presence of bleed-
through fluorescence or lasers (Fig. 2E). Test set 4 was kept held-out and only unlocked immediately before submission of the manuscript
for the final verification of the success of the machine learning models (Fig. 2F).
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and DAPI+ as “other”; while DAPI negative events were clas-
sified as red cell/debris. Gated cell populations were exported
into a file container (.CIF) and served as the ground truth for
downstream analyses. Bleedthrough (spillover) was examined
in a separate experiment with labeled and unlabeled samples
in laser-on and laser-off conditions (Fig. S6).
Image Analysis
Images contained within a .CIF file were stitched into montages
by using a Python script. Cellular objects from the montages
were identified (segmented) using CellProfiler 3.1.6 (14,15). In
the classical image analysis pipeline, object features were
extracted by a series of built-in measurement modules, includ-
ing measuring object intensity, size, shapes, textures, correla-
tions, and subcellular components. Data cleaning and feature
selection were performed by Cytominer (https://github.com/
cytomining/cytominer/) to remove features with near-zero var-
iance and features that have poor correlation across replicates.
Redundant features that are highly correlated were then identi-
fied and only one feature for each of these groups was retained.
After pruning, no pair of features had a correlation greater than
the 95% cutoff threshold (Fig. S3, blue path).
Classical Machine Learning
Various machine learning algorithms were tested and their
hyperparameters were optimized by hyperopt (16) (https://
github.com/hyperopt/hyperopt), including naive Bayes, ran-
dom forest and support vector machine (SVM). We eventu-
ally chose linear SVM as the algorithm of choice for classical
machine learning to achieve an acceptable balance between
performance and computational efficiency. We trained the
classifier to differentiate ALL cells from normal B lympho-
cytes with different combinations of antibody and DNA bio-
markers. In parallel, we iterated the training–testing sets on
20 data sets (leave-one-instance-out) to observe the variance
of prediction accuracy due to the clinical diversity of patients.
Deep Learning
Single-cell images were exported from .CIF files. Data from
fluorescent, bright-field, and dark-field channels were
exported. The images were resized to 48 × 48 pixels by
cropping the peripheral background or padding channel-wise
with noise sampled from the background of actual images
(see code for details: https://github.com/carpenterlab/2019_
doan_leukemia_submitted/blob/
cb642b79fc6ee2c2ae26739147445e90c85ebbf1/deepometry/
parse.py#L163). Additionally, cell images were contrast-
stretched channel-wise to rescale the intensities between the
0.5 and 99.5 percentiles to the full range of uint8, [0, 256).
We adopted ResNet architecture using a Python framework
(17) (https://github.com/broadinstitute/keras-resnet). The net-
work includes 50 convolutional layers, forming repetitive
blocks that perform residual learning, followed by fully con-
nected and softmax layers (Fig. S4). With larger ResNet archi-
tectures (e.g., ResNet200 (18)), we observed no improvements
in accuracy or loss while there was an increase in training
time and resources proportional to the increase in
architecture size. Smaller models, such as a VGG-like archi-
tecture with eight convolutional layers (19), performed well
and were efficient on CPU, but a gap between training and
validation accuracies indicated the opportunities to learn
more features.
We computed categorical cross-entropy as the loss func-
tion and accuracy as our metric, respectively. The model was
compiled using the Adam optimizer with a learning rate of
0.0001. The learning rate was reduced by a factor of 10 when
the validation loss failed to improve for 10 consecutive
epochs. Training was set to stop after 25 consecutive epochs
of no improvement in the validation loss. Objects were cate-
gorized as “leukemic,” “normal” (not leukemic), and “other”
(nonlymphoid nucleated cells such as granulocytes, mono-
cytes, dead or deformed cells). Training and validation data
were randomly undersampled per-patient across cell type to
create a balanced data set. Eighty percent of sampled data was
assigned to the training data set, with the remaining 20%
assigned to validation.
The data were zero-centered using channel-wise mean
subtraction. Means were precomputed from the training set.
Mean subtraction and augmentation were performed in real
time during training and validating operations. Augmentation
included random combinations of horizontal or vertical flips,
horizontal or vertical shifts (up to 50% of the image size), and
rotations up to 180. Augmented training and validation data
were generated in batches of 256 images to maximize GPU
memory resources. We configured the model to train for a
maximum of 512 epochs, though early stopping generally ter-
minated training before 200 epochs. Each epoch ran M/256
steps, with M as the number of training samples, to ensure
the entire training set was seen once per epoch. Validation
occurred once at the end of each epoch, using the entire vali-
dation set with validation step K/256, where K is the number
of validation samples. Test data were comprised entirely of
withheld patient data. Before prediction or evaluation, the
mean pixel values obtained from the training data sets were
subtracted from the test data. No other processing or aug-
mentation was applied.
Data-driven exploration
Extracted features from the high-content analysis pipeline or
deep learning were converted into embeddings, which were
then projected in Tensorboard embeddings visualization
(URL2). For the classical high-content image analysis proce-
dure, we directly calculated t-Distributed Stochastic Neighbor
Embedding (t-SNE)(20) and principal component analysis
(PCA) components from cell features measured by Cel-
lProfiler. For deep learning, we used the pooled features prior
to the last fully connected layer as a feature extractor (pool5
layer of ResNet50). We then applied this feature set to the test
data to obtain 2048 deep learning embeddings for each object
in the data set. We then utilized Tensorboard built-in t-SNE
and PCA functions to visualize the embeddings in 3D sca-
tterplots. Using interactive gates on t-SNE/PCA plots of Ten-
sorBoard, one also has options to isolate objects-of-interest
for further analysis.
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RESULTS
Using diagnostic and follow-up bone marrow aspirates taken
during remission induction from children with B lineage ALL
and with the leukemia-associated immunophenotype (n = 30,
collected over two and a half years), we first trained a
convolutional neural network to separate IFC cell images into
three classes: ALL blasts (CD19+CD10+CD34+/− and
CD45+/−), normal B lymphocytes (CD19+CD10−CD34− and
CD45+), and “other” nucleated cells—denoting granulocytes,
monocytes, deformed/dead cells etc.). We adopted ResNet
architecture (17), which includes 50 convolutional layers,
Figure 2. Legend on next page.
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forming repetitive blocks that perform residual learning,
followed by fully connected and softmax layers (see Methods,
URL1, Supporting Information). Using all the image channels
(fluorescently tagged antibodies, together with a nuclear dye
and bright-field and dark-field) of the red-cell-lysed sam-
ples, this network predicted leukemic cells in unseen test
samples with 98.2% accuracy, compared to a reference of
gating on CD45/CD10/CD34/CD19 antibody stains fol-
lowing the United Kingdom-standardized flow residual
disease estimation method (13). (Test 1: Fig. 1, second
column). We then sought to determine which biomarkers
were essential by excluding them one at a time (during
training and testing) and reassessing the classification
performance.
Surprisingly, removing several fluorescent biomarker
channels did not dramatically reduce the ability of the net-
work to detect leukemia cells. In fact, using only the label-free
images (bright-field and dark-field) achieved a rate of 90.3%
in leave-one-out testing (Fig. 2A) and 88.6% on patient sam-
ples completely excluded from the training protocol (Fig. 2B).
This finding aligns well with other recent developments in
label-free bioimage analysis using deep learning (21,22),
which reconstruct fluorescent label channels from bright-field
images only. These advances demonstrate that label-free
imaging contains more information than what is visible to the
naked eye, and deep convolutional neural networks can accu-
rately recover this hidden information. Consistent with the
high accuracy of label-free classification, the features extracted
by the penultimate layer (Fig. S4) of our trained deep network
suffice to position cells into clusters that corresponded well
with the true class identities (Fig. 2C).
For comparison, conventional machine learning (linear
SVM) on morphological features, extracted by standard image
processing (14,15), yielded accuracies ~4% to 15% lower to
that of deep learning (Fig. S5). While improvements might be
possible by further algorithm selection and tuning, deep
learning offers the advantage of eliminating several steps in
the traditional machine learning workflow—such as segmen-
tation, feature extraction, and feature selection—which
significantly simplifies the ALL detection protocol. In addi-
tion, the huge numbers of cells available from clinical samples
are a good fit for further improving the deep learning model
in the future. We also observed that the chosen ResNet50
architecture performed better on our single-cell IFC images of
size 48 × 48 pixels than very large networks (such as
ResNet101, ResNet200) or small models such as VGG (see
Methods and Supporting Information).
Next, we validated the strategy using clinically relevant
metrics in a held-out set of samples. We used the trained neu-
ral network to estimate the number of leukemic cells in
unannotated white cells (in-focus singlets) to compute the
leukemia percentage for each patient (Test 2 in Fig. 1 third
column, Figure 2D). This readout is the standard diagnostic
score used in clinical practice to determine patient status. We
compared the leukemia burden obtained with neural network
predictions against that reported in the patient’s record to
estimate the performance of our proposed method in the
real-world diagnostic task. The network identified leukemic
cells from a mixed population of bone marrow cells with an
accuracy of >88% based solely on the bright-field and dark-
field images of IFC, comparable to the use of a full panel of
four specific antigenic biomarkers and human-curated ALL
counts. The commonly accepted cutoff to define slow early
responding patients is 25% MRD (2,3), shown as a red dashed
line in Figure 2D. At this cutoff, sensitivity and specificity of
our method was 100%, that is, the method identified all true
positives (>25% leukemia cells) and true negatives (<25%). At
a 10% residual disease cutoff, sensitivity remained at 100%
but specificity lowered to 80% (Fig. 2D; LK175 (Day 8) and
LK155 (Day 28) are discordant, with the label-free method
overestimating residual disease).
To confirm that the trained machine learning algorithms
were not affected by bleed-through fluorescence or by the
presence of laser illumination in the label-free channels, we
measured unlabeled samples with the instrument laser fully
off (Test 3 in Fig. 1, Figure 2E, and S6). A bone marrow sam-
ple after Day 8 of treatment initiation (containing >1 million
Figure 2. Label-free identification of ALL cells by ResNet50 corresponds well with biomarker-based analysis. (A) Prediction results on each of
11 test data entries from five patients, who have data at the time of presentation and during treatment (average accuracy from single-cell
classification) (Test 1). The first column reports average accuracy across samples using all channels; subsequent columns correspond to
incremental dropping of the next channel. BF, bright-field; DF, dark-field. Boxplots show the median line, first and third quartiles. Whiskers are
drawn to double interquartile range (+2IQR). Diamonds represent data events that are outside the low and high whisker ends. (B) Three-class
single-cell classification using bright-field and dark-field channels (Test 1). Confusion matrix for three categories, n = 218,747 ground-truth cells
pooled from 11 test sets. (C) Clustering of 9,025 cells randomly sampled from patient LK157 at the time of presentation based on deep learning
features. 3D t-Distributed Stochastic Neighbor Embedding (t-SNE)(20) presentations based on 2,048 label-free feature vectors for each cell from
the second-to-last layer of the trained neural network, ResNet50, are shown. The t-SNE calculation was stabilized after 400 iterations at
perplexity of 30. Colors coded according to true class labels: Leukemic cells (blue), normal B lymphocytes (red), other cell types (yellow). The
magnified images display true bright-field channel, randomly zoomed at each cluster. Example data with overlaid images http://projector.
tensorflow.org/?config=raw.githubusercontent.com/minh-doan/Deeplearning_LabelFree_Leukemia/master/Publish/DL_supervised/Data/Step4/
Output/projector_config.pbtxt can be visualized with a web-based projector. (D) Comparison between human-curated manual gates and label-
free deep learning in predicting residual disease fraction (Test 2). The prediction on each sample was performed on the DAPI-positive popula-
tion of in-focus, white blood cells, which is a mixture of leukemic blasts, normal B lymphocytes, other mature and immature hematopoietic
cells such as granulocytes and monocytes. Red dash-line is 25%—the threshold of treatment effectiveness of chemotherapy. (E) Summary of
residual disease estimated by deep learning using information in bright-field channel of labeled/unlabeled samples (each with laser on/off set-
tings) (Test 3). Residual disease fraction was calculated as the percentage of predicted leukemic cells over the whole population of unannotated
in-focus single cells. For reference, human-curated manual residual disease fraction (last blue column) was estimated based on the stained ver-
sion with laser on. (F) Result of label-free deep learning residual disease readout (yellow columns) on unannotated in-focus single cells in held-
out data (Test 4). Blue columns are residual disease readout reported by standard clinical flow cytometric protocol. LK881 and LK919 (asterisks)
are relapsed ALL patients. [Color figure can be viewed at wileyonlinelibrary.com]
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cells) was split into two portions; one was stained with fluo-
rescent labeling reagents and one was left unstained, each was
further split into two parts, one was measured with laser exci-
tation (laser-on) and one with all lasers turned off. Whether
samples had been labeled or left unlabeled, and whether the
laser was on or off, leukemia burden was 9–13% (Fig. 2E).
The final test set was kept held-out and only unlocked imme-
diately before submission of the manuscript for the final veri-
fication of the success of the machine learning models
(Fig. 2F). Here, the results reaffirmed the performance of the
neural network on label-free images to resemble human man-
ual evaluation using labeled data, achieving 100% sensitivity
and specificity at the level of 25% leukemic load.
DISCUSSION
In summary, we demonstrate identification of residual leuke-
mic cells in clinical samples without specific antibody tags.
Although the use of multiple antibody-conjugated markers
provides 11 percentage points better in classification accuracy,
we observed that the morphological features from label-free
channels were still sufficient to achieve clear discrimination of
ALL cell phenotypes, even when they are a very small per-
centage of the total white cells. The strong performance on
hold-out patient samples indicates robustness to technical
and patient heterogeneity. Clinical deployment would require
a careful collection of data across sites and operators to train
a robust deep learning model for each type of instrument
and sample preparation protocol. Nevertheless, eliminating
the use of laser-based instruments and staining protocols
should inherently reduce patient-to-patient and facility-to-
facility variations. We provide open-source scripts https://
github.com/carpenterlab/2019_doan_leukemia_submitted to
facilitate reproducibility of the study, testing on expanded
samples, and application to new clinical and basic biology
problems.
Although this study is to our knowledge the first to test
deep learning on counting ALL cells label-free using imaging
flow cytometry, it is consistent with related strategies that
took alternate sample measurement or different computa-
tional approaches on other blood disorders. For example,
Matek et al. used convolutional neural networks to achieve
human-level recognition of blast cells in acute myeloid
leukemia (AML), using expert microscopic examination of
histological stained blood smears on glass slides instead of a
flow-based system (23). The approach was not label-free,
required smearing samples, and unlike our presented
approach it relied on subjective inputs from experts rather
than biomarker labeling for training. Ugele et al. used label-
free digital holographic microscopy to achieve convincing
classification of nine leukocyte types, as well as different leu-
kemia subtypes principally at diagnosis (24). This is unfortu-
nately not suited to minimal residual disease detection
because a high throughput modality is required (such as
imaging flow cytometry)—large numbers of cells need to be
measured to find the rare leukemic cells. As well, that study
did not use convolutional neural networks but instead SVM
trained on conventional features from the images, which is
limited to preengineered features. Kobayashi et al. (25) dem-
onstrated label-free optofluidic time-stretch microscopy, cre-
ating a SVM classifier to identify paclitaxel-treated MCF-7
cells versus untreated cells at an accuracy of 92%. Also on a
microfluidic flow platform, Dannhauser et al. (26) used light
scattering properties to discriminate peripheral blood mono-
nuclear blood cell types, including T-, B-lymphocytes, and
monocytes in different stages of lymphoid and myeloid
leukemia. Lee et al. (27) used an ultrafast quantitative
phase imaging (QPI) flow cytometer to classify multiple
human leukemic cell types at ~92–97% accuracy based on
subcellular biophysical profiles. Similarly, Mugnano et al.
(28) used QPI to detect characteristic morphologies of red
blood cells in several inherited anemias, such as iron-deficiency
anemia, thalassemia, hereditary spherocytosis, and congenital
dyserythropoietic anemia. We believe our results will encourage
others to combine the properties of many of these studies and
develop new methods for translational disease monitoring using
deep learning on label-free samples from commercially available
instrumentation.
If adapted to clinical use, label-free approaches could
offer simplicity and robustness, as well as time and cost sav-
ings. While the presented strategy does not have the accuracy
to completely replace morphology or residual disease tests per
se at this stage, the accuracy is acceptable for the clinically
meaningful cutoff level of 25% ALL cells, which may be espe-
cially useful in resource-poor regions, which lack trained
hematopathologists. It may allow slow early responders to be
easily detected and prioritize the borderline cases for assess-
ment by experts. As well as assessing treatment response in
ALL, it may also be feasibly applied to diagnose ALL and to
differentiate ALL from lymphoblastic lymphoma, as a dis-
criminatory parameter is the level of leukemic cells in the
bone marrow.
Looking further to the future, the requirement of only
bright-field and dark-field data could catalyze an opportunity
for a simplified, label- and laser-free, hand-held imaging
cytometer that would allow automated, point-of-care residual
disease testing. A simple, compact, lightweight, optofluidic
system already exists; it is fitted with a cheap, diode light
source and attached to a cell phone (29). While our network
took weeks to train on a GPU (NVIDIA Titan X), once the
classifier is learned, millions of cells might be imaged by a
simplified cytometer, examined by the trained algorithm, and
a residual disease readout delivered within minutes (for cell
images of size 48 × 48 pixels, the typical inference speed is
~375,000 cells/min on a Titan X at batch size of 512). We
would expect the accuracy and robustness of our method to
improve with the expansion of the training data set, a tactic
that can close the accuracy gap between clinical specialist and
machine learning (30).
Our results provide a concrete example of deep learning
on single cells to enable personalized medicine. While the
focus here is ALL, residual disease monitoring is a key
response biomarker in all chronic and acute leukemias, multi-
ple myeloma, and some nonhematological cancers for
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circulating tumor cells (31–33). We expect the strategy and
code provided here to have broad clinical applicability across
a range of cancer types.
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